Literature DB >> 27089810

50years of oral lipid-based formulations: Provenance, progress and future perspectives.

Orlagh M Feeney1, Matthew F Crum2, Claire L McEvoy1, Natalie L Trevaskis1, Hywel D Williams3, Colin W Pouton1, William N Charman1, Christel A S Bergström4, Christopher J H Porter5.   

Abstract

Lipid based formulations (LBF) provide well proven opportunities to enhance the oral absorption of drugs and drug candidates that sit close to, or beyond, the boundaries of Lipinski's 'rule-of-five' chemical space. Advantages in permeability, efflux and presystemic metabolism are evident; however, the primary benefit is in increases in dissolution and apparent intestinal solubility for lipophilic, poorly water soluble drugs. This review firstly details the inherent advantages of LBF, their general properties and classification, and provides a brief retrospective assessment of the development of LBF over the past fifty years. More detailed analysis of the ability of LBF to promote intestinal solubilisation, supersaturation and absorption is then provided alongside review of the methods employed to assess formulation performance. Critical review of the ability of simple dispersion and more complex in vitro digestion methods to predict formulation performance subsequently reveals marked differences in the correlative ability of in vitro tests, depending on the properties of the drug involved. Notably, for highly permeable low melting drugs e.g. fenofibrate, LBF appear to provide significant benefit in all cases, and sustained ongoing solubilisation may not be required. In other cases, and particularly for higher melting point drugs such as danazol, where re-dissolution of crystalline precipitate drug is likely to be slow, correlations with ongoing solubilisation and supersaturation are more evident. In spite of their potential benefits, one limitation to broader use of LBF is low drug solubility in the excipients employed to generate formulations. Techniques to increase drug lipophilicity and lipid solubility are therefore explored, and in particular those methods that provide for temporary enhancement including lipophilic ionic liquid and prodrug technologies. The transient nature of these lipophilicity increases enhances lipid solubility and LBF viability, but precludes enduring effects on receptor promiscuity and off target toxicity. Finally, recent efforts to generate solid LBF are briefly described as a means to circumvent the need to encapsulate in soft or hard gelatin capsules, although the latter remain popular with consumers and a proven means of LBF delivery.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  In vitro digestion; Lipid based formulations; Poorly water soluble drugs; Self-emulsifying drug delivery systems; Solubilisation; Supersaturation

Mesh:

Substances:

Year:  2016        PMID: 27089810     DOI: 10.1016/j.addr.2016.04.007

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  45 in total

1.  Temperature- and rigidity-mediated rapid transport of lipid nanovesicles in hydrogels.

Authors:  Miaorong Yu; Wenyi Song; Falin Tian; Zhuo Dai; Quanlei Zhu; Ejaj Ahmad; Shiyan Guo; Chunliu Zhu; Haijun Zhong; Yongchun Yuan; Tao Zhang; Xin Yi; Xinghua Shi; Yong Gan; Huajian Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-05       Impact factor: 11.205

Review 2.  Lipids in the Stomach - Implications for the Evaluation of Food Effects on Oral Drug Absorption.

Authors:  Mirko Koziolek; Frédéric Carrière; Christopher J H Porter
Journal:  Pharm Res       Date:  2018-02-08       Impact factor: 4.200

3.  Lipophilicity in Drug Development: Too Much or Not Enough?

Authors:  Christel A S Bergström; Mehran Yazdanian
Journal:  AAPS J       Date:  2016-07-08       Impact factor: 4.009

4.  Quantifying In Vivo Luminal Drug Solubilization -Supersaturation-Precipitation Profiles to Explain the Performance of Lipid Based Formulations.

Authors:  Yusuke Tanaka; Erin Tay; Tri-Hung Nguyen; Christopher J H Porter
Journal:  Pharm Res       Date:  2020-02-03       Impact factor: 4.200

5.  Alkoxycarbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria.

Authors:  Lisa Frueh; Yuexin Li; Michael W Mather; Qigui Li; Sovitj Pou; Aaron Nilsen; Rolf W Winter; Isaac P Forquer; April M Pershing; Lisa H Xie; Martin J Smilkstein; Diana Caridha; Dennis R Koop; Robert F Campbell; Richard J Sciotti; Mara Kreishman-Deitrick; Jane X Kelly; Brian Vesely; Akhil B Vaidya; Michael K Riscoe
Journal:  ACS Infect Dis       Date:  2017-09-27       Impact factor: 5.084

Review 6.  Current Status of Supersaturable Self-Emulsifying Drug Delivery Systems.

Authors:  Heejun Park; Eun-Sol Ha; Min-Soo Kim
Journal:  Pharmaceutics       Date:  2020-04-16       Impact factor: 6.321

7.  Incorporation of lipolysis in monolayer permeability studies of lipid-based oral drug delivery systems.

Authors:  Tanmoy Sadhukha; Buddhadev Layek; Swayam Prabha
Journal:  Drug Deliv Transl Res       Date:  2018-04       Impact factor: 4.617

8.  Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability.

Authors:  Avital Beig; Noa Fine-Shamir; David Lindley; Jonathan M Miller; Arik Dahan
Journal:  AAPS J       Date:  2017-02-15       Impact factor: 4.009

9.  Novel cationic supersaturable nanomicellar systems of raloxifene hydrochloride with enhanced biopharmaceutical attributes.

Authors:  Atul Jain; Rajpreet Kaur; Sarwar Beg; Varun Kushwah; Sanyog Jain; Bhupinder Singh
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

10.  Supersaturated-Silica Lipid Hybrids Improve in Vitro Solubilization of Abiraterone Acetate.

Authors:  Hayley B Schultz; Paul Joyce; Nicky Thomas; Clive A Prestidge
Journal:  Pharm Res       Date:  2020-03-31       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.